

Reimbursement in Ireland

AGENDA

SEPT 18th PART 1

TIME	TOPIC	SPEAKER
9.00-9.10	Introduction & Objectives	Brenda Dooley, CEO, AXIS
9.10-9.30	Overview of the Market Access Landscape	Brenda Dooley, CEO, AXIS
9.30-9.45	Using Expert Opinion in Irish Reimbursement applications	James Bohanna, Medical Manager, AXIS
9.45-10.00	Finding Irish data for your Irish Submission	Cillian Copeland, Senior Analyst, AXIS
10.00-10.15	Developing a robust Rapid Review submission	James Bohanna, Medical Manager, AXIS
10.15-10.30	Case study A Rapid Reviews – the AXIS experience	Small group breakout session led by AXIS team member
10.30-10.40	COFFEE BREAK	
10.40-10.55	Patient Engagement in the Irish HTA Process	Marian Hernon, HTA Manager, AXIS
10.55-11.10	When Rare is not so Rare Reimbursement of Orphan Medicines	Brenda Dooley, CEO, AXIS
11.10-11.30	The role of the Irish Patient Organisation in decisions on reimbursement of Medicines	Mr Philip Watt, CEO, Cystic Fibrosis Ireland Chairman, Rare Diseases Task Force
11.30-11.45	Having Pricing discussions in Ireland	Brenda Dooley, CEO, AXIS
11.45-12.05	Funding the costs of New medicines in Ireland	Dr Valerie Walshe, Senior Health Economist, HSE
12.05-12.10	Questions and Answers	
12.15	CLOSE OF PART 1	

GUEST SPEAKERS



Mr Philip Watt

Philip Watt is CEO of Cystic Fibrosis Ireland. He is also Chairperson of the Rare Disease Taskforce and the Irish Donor Network and a former Chairperson of Health Research Charities Ireland (HRCI) and a founder member of the Irish Health Research Forum.



Dr. Valerie Walshe

Senior Health Economist, Health Service Executive (HSE). Valerie received her PhD from TCD in 2008, under the guidance of Prof. Michael Barry, examining the cost effectiveness of various drugs reimbursed in Ireland and maintains her interest in this area by working with the Medicines Management Programme and advising on drug reimbursement within the HSE.

Reimbursement in Ireland

AGENDA

SEPT 23rd PART 2

TIME	TOPIC	SPEAKER
9.00-9.10	Introduction & Recap of Part 1	Brenda Dooley, CEO, AXIS
9.10-9.20	A look at Reimbursement Timelines in Ireland	Cillian Copeland, Senior Analyst, AXIS
9.20-9.40	How to Optimise your HTA Submission for the NCPE assessment	Marian Hernon, HTA Manager, AXIS
9.40-9.50	The importance of the Budget Impact in your HTA	James Bohanna, Medical Manager, AXIS
9.50-10.15	Case study B HTA submission - the AXIS experience	Small group Virtual Breakout session
10.15- 10.35	The Acute Hospitals Drug Management Programme	Fionnuala King, Chief Pharmacist, Acute Hospitals Drug Management Programme
10.35- 10.45	COFFEE BREAK	
10.45-11.00	Oncology Submissions in Ireland	Marian Hernon, HTA Manager, AXIS
11.00-11.15	BeNeLuxA and Ireland - the future?	James Bohanna, Medical Manager, AXIS
11.15-11.30	Role of the Medicines Management Programme in Ireland	Brenda Dooley CEO, AXIS
11.30-11.50	The National Cancer Control Programme and Reimbursement of Oncology medicines	Patricia Heckmann, Chief Pharmacist NCCP
11.50-12.00	Questions and Answers	
12.00-12.10	Checklist for Success	AXIS Team
12.15	CLOSE OF PART 2	

GUEST SPEAKERS



Fionnuala King

Fionnuala King is the Chief Pharmacist for the Acute Hospitals Drug Management Programme. Fionnuala qualified as pharmacist at Robert Gordon University, completed post-graduate studies in Clinical Pharmacy at the University of London, a Masters in Leadership and Organisational Learning in the Royal College of Surgeons Dublin.



Patricia Heckmann

Chief Pharmacist & National Network Lead - Systemic Therapy Programme, National Cancer Control Programme (NCCP). Patricia Heckmann qualified as a pharmacist at the University of Dublin, Trinity College, before completing a Masters in Health Informatics.